Pfizer, Merck strike $2.85B deal as hope of AstraZeneca merger wanes

Pfizer Inc. entered into an agreement Monday with Merck KGaA to jointly develop and commercialize an immunotherapy product that Merck KGaA has under development as a potential treatment for a variety of cancers...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.